Marshall Wace
BHVN

Marshall Wace’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Marshall Wace’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,406
Closed -$2.93M – 3926
2022
Q3 		$2.93M Sell
19,406
-1,909,218
-99% -$283M 0.01% 1768
2022
Q2 		$281M Sell
1,928,624
-472,660
-20% -$60.4M 0.58% 19
2022
Q1 		$285M Sell
2,401,284
-397,173
-14% -$49.5M 0.54% 21
2021
Q4 		$386M Buy
2,798,457
+80,272
+3% +$10.2M 0.71% 16
2021
Q3 		$378M Sell
2,718,185
-14,183
-0.5% -$1.77M 1.57% 1
2021
Q2 		$265M Sell
2,732,368
-44,099
-2% -$3.58M 1.2% 5
2021
Q1 		$190M Buy
2,776,467
+219,915
+9% +$17.8M 0.87% 11
2020
Q4 		$219M Buy
2,556,552
+28,702
+1% +$2.43M 1.19% 11
2020
Q3 		$164M Buy
2,527,850
+26,406
+1% +$1.73M 1.05% 15
2020
Q2 		$183M Sell
2,501,444
-61,999
-2% -$3.3M 1.28% 7
2020
Q1 		$87.2M Buy
2,563,443
+2,312,881
+923% +$106M 0.87% 17
2019
Q4 		$13.6M Sell
250,562
-287,235
-53% -$14.2M 0.09% 247
2019
Q3 		$22.4M Buy
537,797
+251,836
+88% +$10.6M 0.18% 130
2019
Q2 		$12.5M Buy
285,961
+278,863
+3,929% +$15.7M 0.1% 226
2019
Q1 		$365K Buy
+7,098
New +$307K ﹤0.01% 1222

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Marshall Wace's BHVN Position: Q4 2022 in Review

Marshall Wace sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 19,406 shares — an estimated $2.93M sold.

Marshall Wace first reported a position in BHVN in Q1 2019 and held it in 15 quarters. The position peaked at $386M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Marshall Wace reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 19,406 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2.93M.
  • Marshall Wace first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 15 quarters.
  • Marshall Wace's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $386M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.